Write Hatem Mohamed

Jamjoom Pharma, a leading pharmaceutical company in the Middle East and Africa (MEA), has signed a Facility Sale and Purchase Agreement with Pfizer Saudi Limited Company to acquire a pharmaceutical manufacturing facility located in King Abdullah Economic City (KAEC), Saudi Arabia.The facility specializes in the manufacturing and packaging of oral solid dosage (OSD) pharmaceutical products and operates across the full production chain, supported by on-site quality control laboratories. The acquisition marks a strategic addition to Jamjoom Pharma’s manufacturing network and is set to significantly enhance its production and operational capabilities within the Kingdom.The move aligns with Jamjoom Pharma’s long-term growth strategy and its commitment to advancing local manufacturing capabilities in Saudi Arabia, directly supporting national priorities around localization and industrial development under Vision 2030. The new site will also strengthen regional supply chain resilience and expand access to high-quality, affordable healthcare solutions for patients across the Middle East and Africa.Jamjoom Pharma emphasized that the transaction reflects its unwavering commitment to “Quality Without Compromise,” building on Pfizer’s legacy of stringent quality standards. The company also affirmed its commitment to ensuring workforce stability at the KAEC site and fostering a culture of development that leverages the team’s established capabilities.“This agreement marks an important milestone in our growth journey and reflects our commitment to strengthening our manufacturing capabilities within the Kingdom,” said Tarek Hosni, Chief Executive Officer of Jamjoom Pharma. “We are focused on building a scalable platform that supports sustainable growth while maintaining the highest standards of quality and operational excellence.”The milestone supports Jamjoom Pharma’s vision to become the leading healthcare organization across MEA by 2030, positioning the company for sustainable growth in a rapidly evolving healthcare landscape.Completion of the transaction remains subject to satisfaction of certain customary conditions, including obtaining the necessary regulatory approvals. Jamjoom Pharma stated it will announce any material developments related to the transaction in accordance with applicable regulatory requirements.